)
Visual
earnings real time
Beijing Wantai Biological Pharmacy Enterprise Co.
Beijing Wantai Biological Pharmacy Enterprise Co. (603392) investor relations material
Beijing Wantai Biological Pharmacy Enterprise Co. Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary29 Oct, 2025
Executive summary
Revenue for the first nine months of 2025 was RMB 1.50 billion, down 23.1% year-over-year, with a net loss attributable to shareholders of RMB 173.4 million, reversing a profit in the prior year.
The company faced significant declines in profit due to market adjustments and government procurement impacts on vaccine and IVD segments.
Despite financial setbacks, the company advanced product innovation, expanded international vaccine sales, and achieved key regulatory milestones.
Financial highlights
Operating income for Q3 2025 was RMB 654.8 million, up 12.5% from the same quarter last year.
Net loss for Q3 was RMB 29.4 million, a 576.3% increase in losses year-over-year.
Net cash flow from operating activities for the first nine months was RMB 7.3 million, down 96.3% year-over-year.
Basic and diluted EPS for the first nine months were both -0.14, compared to 0.21 last year.
Total assets at September 30, 2025, were RMB 14.37 billion, down 2.2% from year-end 2024.
Outlook and guidance
The company is focusing on differentiated innovation, strengthening its sales network, and accelerating international market expansion to foster new growth drivers.
Continued investment in R&D and product quality aims to support stable growth in diagnostic and vaccine businesses.
Mitigation strategy for market/procurement impact
9-valent HPV/molecular diagnostics revenue outlook
Sustain international vaccine growth strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- EMCURE
Q3FY26 revenue rose 20% YoY, PAT up 48%, with margin gains and robust global growth. - 500870
Record revenue and 8% volume growth in FY25, with robust margins and strong dividend payout. - SOI
Q3 revenue €160m, up 18% sequentially, Edge & Cloud AI up 27%, Q4 set for 20% growth. - IFX
Q1 2026 revenue rose 7% year-over-year, driven by AI demand and increased investments. - ELS
2025 revenue soared 11x to $23M, with strong cash, major contracts, and a robust 2026 outlook. - V2RETAIL
Q3 FY26 saw 57% revenue and 99% PAT growth, with robust expansion and capital infusion. - UBSG
Net profit surged 53% in FY25, with integration and cost savings driving strong results. - 524348
Q3 FY26 revenue up 8% and PAT up 58%, with margin recovery and new projects ramping up. - BOTX
Record gold output and profit, with investments driving strong growth outlook for 2026. - BAJAJFINSV
Q3 FY26 profit was flat at ₹2,229 crore as strong growth was offset by one-time charges.
Next Beijing Wantai Biological Pharmacy Enterprise Co. earnings date
Q4 202521 Apr, 2026
Beijing Wantai Biological Pharmacy Enterprise Co.
Next Beijing Wantai Biological Pharmacy Enterprise Co. earnings date
Q4 202521 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. specializes in the research, development, production, and distribution of biopharmaceutical products. The company focuses on diagnostic reagents, vaccines, and other biological products used in the prevention and detection of infectious diseases. Its offerings serve healthcare institutions, laboratories, and public health organizations, aiming to support disease prevention and health management. The company is headquartered in Beijing, China, and its shares are listed on the SSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage